Retina

The novel dual-port cutter, designed for use with the Stellaris Elite platform, offers increased flow rate and reduced cutter vibration.

Ultra-widefield imaging reveals early retinal risk in paediatric patients.

Professor Alió reflects on a new comprehensive volume dedicated to aging in ophthalmology

Temporal optical coherence tomography modelling may improve longitudinal disease tracking.

The dual-function phaco-vitrectomy platform is cleared for European commercialization, with launch targeted for Q3 2026.

Prof. Sobha Sivaprasad discusses why GA's multistage nature demands a broader therapeutic approach—and what evidence will shape clinical decision-making.

The trial, sponsored by ONL Therapeutics, aims to enrol approximately 324 patients across sites in Europe, the United States, and Canada.

The 3rd Winterthur Ophthalmology Symposium in Winterthur, Switzerland, on 12–13 March 2026 will feature plenary talks, hands-on workshops, satellite sessions, poster presentations, and a gala honoring the Otto Haab Medal.

An ophthalmology resident shares insights from experiences across Mexico, Europe, and the US.

EYE PCR’s fixOflex is now eligible for European market introduction, providing clinicians with a method of preserving the capsular bag’s form after cataract surgery.

The 22nd International Scientific Symposium on Ophthalmic Imaging will take place 18–19 September 2026 in Singapore, marking an expanded scientific scope while maintaining its focus on imaging in research and clinical practice.

Retina specialists showcase innovation and precision in retinal care

A recent study reveals that retinal microvascular changes in thyroid eye disease reflect disease activity, offering potential for improved diagnostics and treatment strategies.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

Navigating the labyrinth of IRD research to identify objective, clinically meaningful outcomes.

Dr. Quan Dong Nguyen presents interim data from the phase 3 DRAGON study on a potential first therapy for adolescent Stargardt disease.

The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe.

Dr. Hartnett highlights new approaches to ROP care and the changing ethical, clinical, and technological landscape in a guest lecture.

Priyanka Sanghi, BSc, MSc, MBBS, highlights how fundus autofluorescence and optical coherence tomography may help uncover long-term retinal footprints invisible to standard examination.

Prof Dr Rajvardhan Azad explains how unified guidelines, AI-driven tools, and cross-disciplinary collaboration could transform outcomes for premature infants.

Dr. J. Peter Campbell discusses the technologies shaping retinopathy of prematurity detection, clinical integration, and global implementation.

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.

The company noted that this approval marks Celltrion's first Health Canada-approved biologic product in ophthalmology.